(Total Views: 610)
Posted On: 11/05/2021 2:01:04 PM
Post# of 154115
Learned a few things:
(1) Focusing on CD16/critical in Brazil, not severe, and now doing interim analysis at just 50 subjects.
(2) For NASH, did 60 in double-blind portion at 700 mg (to be unblinded and reported in December, hopefully), and doing 30 in open-label portion at 350 mg. The first 5 at 350 were what was reported earlier this week. They will continue to dribble out results from this open label portion as the results accrue, and might consider BTD for NASH if results are good. I think he said so far average fat suppression was ~25% (range 5-45%?), and fibrosis decrease 10% (range -2%-12%?) based on MRI based biomarkers.
(1) Focusing on CD16/critical in Brazil, not severe, and now doing interim analysis at just 50 subjects.
(2) For NASH, did 60 in double-blind portion at 700 mg (to be unblinded and reported in December, hopefully), and doing 30 in open-label portion at 350 mg. The first 5 at 350 were what was reported earlier this week. They will continue to dribble out results from this open label portion as the results accrue, and might consider BTD for NASH if results are good. I think he said so far average fat suppression was ~25% (range 5-45%?), and fibrosis decrease 10% (range -2%-12%?) based on MRI based biomarkers.
(5)
(0)
